biosimilars pipeline
Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated ...
Unlike other biosimilar markets, competition among follow-on products of HUMIRA® is very high and several eager companies are attempting to carve out a share ...
Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated ...
Unlike other biosimilar markets, competition among follow-on products of HUMIRA® is very high and several eager companies are attempting to carve out a share ...
Roots Analysis has announced the addition of the “HUMIRA® (Adalimumab) Biosimilars – Pipeline Review and Partnerships” report to its list of offerings. ...
